Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, Progyny Inc (NASDAQ: PGNY) closed at $25.27 down -4.17% from its previous closing price of $26.37. In other words, the price has decreased by -$4.17 from its previous closing price. On the day, 1.64 million shares were traded. PGNY stock price reached its highest trading level at $26.65 during the session, while it also had its lowest trading level at $25.11.
Ratios:
For a deeper understanding of Progyny Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.31 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.26. For the most recent quarter (mrq), Quick Ratio is recorded 2.96 and its Current Ratio is at 2.96. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
On July 08, 2025, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform but kept the price unchanged to $28. JP Morgan Downgraded its Overweight to Neutral on December 02, 2024, while the target price for the stock was maintained at $17.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 28 ’25 when Swartz Allison bought 2,398 shares for $26.87 per share.
Livingston Mark S. sold 21,303 shares of PGNY for $543,226 on Nov 17 ’25. The CHIEF FINANCIAL OFFICER now owns 48,358 shares after completing the transaction at $25.50 per share. On Nov 17 ’25, another insider, Livingston Mark S., who serves as the Officer of the company, bought 21,303 shares for $25.50 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PGNY now has a Market Capitalization of 2178568704 and an Enterprise Value of 1861511552. As of this moment, Progyny’s Price-to-Earnings (P/E) ratio for their current fiscal year is 40.01, and their Forward P/E ratio for the next fiscal year is 26.38. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.48. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.72 while its Price-to-Book (P/B) ratio in mrq is 3.89. Its current Enterprise Value per Revenue stands at 1.467 whereas that against EBITDA is 20.617.
Stock Price History:
The Beta on a monthly basis for PGNY is 0.97, which has changed by 0.77575755 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, PGNY has reached a high of $27.51, while it has fallen to a 52-week low of $13.86. The 50-Day Moving Average of the stock is 16.36%, while the 200-Day Moving Average is calculated to be 14.19%.
Shares Statistics:
For the past three months, PGNY has traded an average of 1.54M shares per day and 1696000 over the past ten days. A total of 86.15M shares are outstanding, with a floating share count of 71.94M. Insiders hold about 16.55% of the company’s shares, while institutions hold 96.59% stake in the company. Shares short for PGNY as of 1763078400 were 6677676 with a Short Ratio of 4.35, compared to 1760486400 on 6564210. Therefore, it implies a Short% of Shares Outstanding of 6677676 and a Short% of Float of 10.7.
Earnings Estimates
. The current assessment of Progyny Inc (PGNY) involves the perspectives of 7.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $0.49, with high estimates of $0.5 and low estimates of $0.46.
Analysts are recommending an EPS of between $1.84 and $1.78 for the fiscal current year, implying an average EPS of $1.81. EPS for the following year is $1.94, with 7.0 analysts recommending between $2.14 and $1.8.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $306.06M this quarter.It ranges from a high estimate of $326.32M to a low estimate of $295.87M. As of. The current estimate, Progyny Inc’s year-ago sales were $298.43MFor the next quarter, 10 analysts are estimating revenue of $343.69M. There is a high estimate of $357.81M for the next quarter, whereas the lowest estimate is $330.2M.
A total of 10 analysts have provided revenue estimates for PGNY’s current fiscal year. The highest revenue estimate was $1.3B, while the lowest revenue estimate was $1.27B, resulting in an average revenue estimate of $1.28B. In the same quarter a year ago, actual revenue was $1.17BBased on 10 analysts’ estimates, the company’s revenue will be $1.4B in the next fiscal year. The high estimate is $1.48B and the low estimate is $1.37B.
